Xybion Digital Inc. Advises Holders of Warrants Issued on November 15, 2021 of Approaching Warrant Expiry
Xybion Digital Inc. Advises Holders of Warrants Issued on November 15, 2021 of Approaching Warrant Expiry
Vancouver, British Columbia--(Newsfile Corp. - July 26, 2023) - Xybion Digital Inc. (TSXV: XYBN) ("Xybion" or the "Company") would like to remind the holders of warrants issued on November 15, 2021 (the "Warrants") of the approaching expiry of their warrants. The Warrants were issued pursuant to the automatic exchange of subscription receipts in connection with the Company's qualifying transaction, under a warrant indenture between Xybion BC Finco Ltd., Xybion Corporation, Gravitas One Capital Corp. and TSX Trust Company (the "Warrant Agent") dated August 6, 2021 (the "Warrant Indenture").
溫哥華，不列顛哥倫比亞省-(Newsfile Corp.-2023年7月26日)-Xybion Digital Inc.(TSXV：XYBN)(“木星“或”公司“)謹此提醒於2021年11月15日發出的認股權證持有人(“認股權證“)他們的認股權證即將屆滿。認股權證是根據與公司符合資格的交易有關的認購收據自動交換而發行的，根據Xybion BC Finco Ltd.、Xybion Corporation、Gravitas One Capital Corp.和多倫多證券交易所信託公司(TSX Trust Company)之間的權證契約《搜查令特務》)日期：2021年8月6日(“認股權證契約“)。
Under the terms of the Warrant Indenture, the Warrants are set to expire at 5:00pm (Toronto time) on November 15, 2023 (the "Expiry Time"). Each Warrant is exercisable to acquire one Common Share at an exercise price of $3.85 and detailed instructions on how to exercise can be found on the Warrant Indenture, available on SEDAR. Any Warrants remaining unexercised after the Expiry Time will be cancelled and will thereafter be of no force or effect.
根據認股權證契約的條款，認股權證將於2023年11月15日(多倫多時間)下午5時到期。“過期時間”)。每份認股權證可行使以3.85美元的行使價格收購一股普通股，有關如何行使的詳細說明可在SEDAR上的認股權證契約中找到。任何在到期後仍未行使的認股權證將被取消，此後將不再具有效力或效力。
For holders wishing to exercise their Warrants, please contact your investment advisor or the Warrant Agent.
如持有人希望行使其認股權證，請聯絡您的投資顧問或認股權證代理人。
About Xybion Digital Inc.
關於Xybion Digital Inc.
Xybion is a global SaaS company that helps enterprise life sciences organizations accelerate new drug development into approved medicines that may save lives and keep employees safe. We digitize drug research and development, laboratory testing, regulatory approvals, and pharmaceutical manufacturing on a single, unified cloud platform that is cost-effective, ready to deploy, and easy to use. Xybion has over 160 clients in 29 countries using its low-code software to accelerate timelines, improve compliance, expand capacity, minimize operating risks, and reduce expenses while keeping employees safe.
Xybion是一家全球性的SaaS公司，幫助企業生命科學組織加快新藥開發，使其成為可能拯救生命和保障員工安全的批准藥物。我們在一個經濟高效、隨時可部署且易於使用的單一統一雲平臺上實現藥物研發、實驗室測試、監管審批和製藥生產的數位化。Xybion在29個國家和地區擁有160多家客戶，使用其低代碼軟體來加快時間表、提高合規性、擴大容量、最大限度地降低運營風險，並在確保員工安全的同時減少費用。
Learn more about Xybion at .
For further information: For more information regarding Xybion Digital Inc., please contact Pradip Banerjee, Chief Executive Officer, PBanerjee@xybion.com, 609-512-5790 x122.
瞭解更多關於Xybion的資訊，請訪問。
有關更多資訊，請訪問：欲瞭解有關Xybion數碼公司的更多資訊，請聯繫首席執行官普拉迪普·班納吉，電子郵件：Pbanerjee@xybion.com，電話：609-512-5790 x122。
The TSX Venture Exchange has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
多倫多證券交易所創業板既沒有批准也沒有反對本新聞稿的內容。多倫多證券交易所風險交易所及其監管服務提供商(該術語在多倫多證券交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.
不得分發給美國新聞通訊社或在美國境內傳播。
To view the source version of this press release, please visit
要查看本新聞稿的源版本，請訪問
譯文內容由第三人軟體翻譯。